Shorena Janelidze1, Sebastian Palmqvist1,2, Antoine Leuzy1, Erik Stomrud1,2, Inge M W Verberk3, Henrik Zetterberg4,5,6,7, Nicholas J Ashton4,8,9,10, Pedro Pesini11, Leticia Sarasa11, José Antonio Allué11, Charlotte E Teunissen3, Jeffrey L Dage12, Kaj Blennow4,5, Niklas Mattsson-Carlgren1,13,14, Oskar Hansson1,2. 1. Clinical Memory Research Unit, Department of Clinical Sciences Malmö, Lund University, Lund, Sweden. 2. Skåne University Hospital, Malmö, Sweden. 3. Neurochemistry Laboratory, Department of Clinical Chemistry, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, the Netherlands. 4. Department of Psychiatry and Neurochemistry, Institute of Neuroscience & Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden. 5. Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden. 6. Department of Neurodegenerative Disease, UCL Institute of Neurology, London, UK. 7. UK Dementia Research Institute at UCL, London, UK. 8. Wallenberg Centre for Molecular and Translational Medicine, University of Gothenburg, Gothenburg, Sweden. 9. King's College London, Institute of Psychiatry, Psychology and Neuroscience, Maurice Wohl Institute Clinical Neuroscience Institute, London, UK. 10. NIHR Biomedical Research Centre for Mental Health and Biomedical Research Unit for Dementia at South London and Maudsley NHS Foundation, London, UK. 11. Araclon Biotech Ltd., Zaragoza, Spain. 12. Eli Lilly and Company, Indianapolis, Indiana, USA. 13. Department of Neurology, Skåne University Hospital, Lund, Sweden. 14. Wallenberg Center for Molecular Medicine, Lund University, Lund, Sweden.
Abstract
INTRODUCTION: We studied usefulness of combining blood amyloid beta (Aβ)42/Aβ40, phosphorylated tau (p-tau)217, and neurofilament light (NfL) to detect abnormal brain Aβ deposition in different stages of early Alzheimer's disease (AD). METHODS: Plasma biomarkers were measured using mass spectrometry (Aβ42/Aβ40) and immunoassays (p-tau217 and NfL) in cognitively unimpaired individuals (CU, N = 591) and patients with mild cognitive impairment (MCI, N = 304) from two independent cohorts (BioFINDER-1, BioFINDER-2). RESULTS: In CU, a combination of plasma Aβ42/Aβ40 and p-tau217 detected abnormal brain Aβ status with area under the curve (AUC) of 0.83 to 0.86. In MCI, the models including p-tau217 alone or Aβ42/Aβ40 and p-tau217 had similar AUCs (0.86-0.88); however, the latter showed improved model fit. The models were implemented in an online application providing individualized risk assessments (https://brainapps.shinyapps.io/PredictABplasma/). DISCUSSION: A combination of plasma Aβ42/Aβ40 and p-tau217 discriminated Aβ status with relatively high accuracy, whereas p-tau217 showed strongest associations with Aβ pathology in MCI but not in CU.
INTRODUCTION: We studied usefulness of combining blood amyloid beta (Aβ)42/Aβ40, phosphorylated tau (p-tau)217, and neurofilament light (NfL) to detect abnormal brain Aβ deposition in different stages of early Alzheimer's disease (AD). METHODS: Plasma biomarkers were measured using mass spectrometry (Aβ42/Aβ40) and immunoassays (p-tau217 and NfL) in cognitively unimpaired individuals (CU, N = 591) and patients with mild cognitive impairment (MCI, N = 304) from two independent cohorts (BioFINDER-1, BioFINDER-2). RESULTS: In CU, a combination of plasma Aβ42/Aβ40 and p-tau217 detected abnormal brain Aβ status with area under the curve (AUC) of 0.83 to 0.86. In MCI, the models including p-tau217 alone or Aβ42/Aβ40 and p-tau217 had similar AUCs (0.86-0.88); however, the latter showed improved model fit. The models were implemented in an online application providing individualized risk assessments (https://brainapps.shinyapps.io/PredictABplasma/). DISCUSSION: A combination of plasma Aβ42/Aβ40 and p-tau217 discriminated Aβ status with relatively high accuracy, whereas p-tau217 showed strongest associations with Aβ pathology in MCI but not in CU.
Authors: Yan Li; Suzanne E Schindler; James G Bollinger; Vitaliy Ovod; Kwasi G Mawuenyega; Michael W Weiner; Leslie M Shaw; Colin L Masters; Christopher J Fowler; John Q Trojanowski; Magdalena Korecka; Ralph N Martins; Shorena Janelidze; Oskar Hansson; Randall J Bateman Journal: Neurology Date: 2021-12-14 Impact factor: 11.800
Authors: Shorena Janelidze; Oskar Hansson; Alexa Pichet Binette; Sebastian Palmqvist; Divya Bali; Gill Farrar; Christopher J Buckley; David A Wolk; Henrik Zetterberg; Kaj Blennow Journal: Alzheimers Res Ther Date: 2022-03-29 Impact factor: 8.823
Authors: Andréa L Benedet; Wagner S Brum; Oskar Hansson; Thomas K Karikari; Eduardo R Zimmer; Henrik Zetterberg; Kaj Blennow; Nicholas J Ashton Journal: Alzheimers Res Ther Date: 2022-02-07 Impact factor: 6.982
Authors: Steffi De Meyer; Jeroen Vanbrabant; Jolien M Schaeverbeke; Mariska Reinartz; Emma S Luckett; Patrick Dupont; Koen Van Laere; Erik Stoops; Eugeen Vanmechelen; Koen Poesen; Rik Vandenberghe Journal: Ann Clin Transl Neurol Date: 2022-05-03 Impact factor: 5.430
Authors: Daniel W Sirkis; Luke W Bonham; Taylor P Johnson; Renaud La Joie; Jennifer S Yokoyama Journal: Mol Psychiatry Date: 2022-04-07 Impact factor: 13.437